<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516448</url>
  </required_header>
  <id_info>
    <org_study_id>TYS-CN-1.1PUMP III(C)</org_study_id>
    <nct_id>NCT03516448</nct_id>
  </id_info>
  <brief_title>Expanding Phase III Study of Tyroserleutide for Injection</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Multicenter Expanding Phase III Clinical Trial to Evaluate the Safety and Efficacy of Injectable Tyroserleutide to Treat Hepatocellular Carcinoma (HCC) (After HCC Resection)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen Kangzhe Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen Kangzhe Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial.&#xD;
      Patients with no tumor lesions 21 days after resection of hepatocellular carcinoma will be&#xD;
      randomized in a 1:1 ratio to 1 of the 2 treatment groups：6mg/d Tyroserleutide (injection), or&#xD;
      placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      -  The first stage includes evaluation of subjects, to assess the inclusion criteria and&#xD;
           exclusion criteria, based on the patients' preoperative imaging results, including tumor&#xD;
           size, tumor characteristics, etc.&#xD;
&#xD;
        -  In the second stage, subjects will return to the hospital 21 days following the baseline&#xD;
           examination.The investigator will determine whether the subject satisfies all&#xD;
           inclusion/exclusion criteria. If all requirements are satisfied, then randomization will&#xD;
           occur 21 days after surgery&#xD;
&#xD;
        -  The day of randomization will be defined as Day 0. Randomized subjects will return to&#xD;
           the hospital and begin cycle 1 on the day of randomization (Day 0). and the relevant&#xD;
           laboratory tests will be performed within 3 days after the end the study drug infusion.&#xD;
&#xD;
        -  Cycles will occur as follows: cycles 2, 3, 4, 5, and n will begin on days 42±3, 70±3,&#xD;
           98±3, 126±3, and 14+28（n-1)± 3, respectively.&#xD;
&#xD;
        -  Based therapeutic drugs are Gan Fu Le&#xD;
&#xD;
        -  the participant will receive medical inspection so as to observe and ensure drug safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">March 24, 2016</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Actual">June 13, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>OS （Overall Survival）</measure>
    <time_frame>3 years</time_frame>
    <description>The time from randomization to death due to any reason</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RFS(Recurrence Free Survival)</measure>
    <time_frame>3 years</time_frame>
    <description>The time from randomization to recurrence, metastasis or death due to any reason</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">352</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>the Tyroserleutide for injection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>the Tyroserleutide for injection at the dosage of 6mg/d Gan Fu Le Tablets，6 tablets,po,tid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>the placebo Gan Fu Le Tablets，6 tablets,po,tid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gan Fu Le Tablets</intervention_name>
    <description>6 Tablets，tid,po</description>
    <arm_group_label>the Tyroserleutide for injection</arm_group_label>
    <arm_group_label>the placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tyroserleutide for injection</intervention_name>
    <description>6mg/d, 5days,ivgtt</description>
    <arm_group_label>the Tyroserleutide for injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0mg/d, 5days,ivgtt</description>
    <arm_group_label>the placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Aged ≥ 18 years and ≤ 75 years old, male or female&#xD;
&#xD;
          -  Subject underwent resection of hepatocellular carcinoma (confirmed by pathology)&#xD;
&#xD;
          -  The tumor characteristics must meet the following:A single tumor with a maximum&#xD;
             diameter &gt;5cm ,Preoperative imaging, or Intraoperative visual observation.;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concomitant malignant tumor(s) in other systems is/are present&#xD;
&#xD;
          -  Tumor thrombosis in the branch of portal vein or in hepatic vein is detected by&#xD;
             preoperative imaging or observed during the surgery&#xD;
&#xD;
          -  The subject received any previous systemic anti-HCC therapy prior to the resection&#xD;
             surgery (except the resection surgery), such as liver transplantation, intervention,&#xD;
             ablation, radiotherapy, chemotherapy, molecular targeted therapy or other anti-HCC&#xD;
             therapy&#xD;
&#xD;
          -  The subject took Sorafenib prior to randomization&#xD;
&#xD;
          -  The subject took other study/investigational drugs 7 days prior to randomization&#xD;
&#xD;
          -  The subject took Kang Laike injection/soft capsule，or Jinke Huaier granule 7 days&#xD;
             prior to randomization&#xD;
&#xD;
          -  The subject has central nervous system disease, mental illness, unstable angina,&#xD;
             congestive heart failure, severe arrhythmia or other severe uncontrolled diseases&#xD;
&#xD;
          -  The subject has history of investigational drug or similar drug allergy&#xD;
&#xD;
          -  The baseline examination indicates that infection, bleeding, bile leakage, or other&#xD;
             postoperative complications are present&#xD;
&#xD;
          -  The subject is pregnant, lactating, or urine pregnancy test result is positive&#xD;
&#xD;
          -  Baseline (post-resection) examination exist tumor recurrence or metastasis;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>July 4, 2017</study_first_submitted>
  <study_first_submitted_qc>May 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>May 3, 2018</last_update_submitted>
  <last_update_submitted_qc>May 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

